Open adjunctive ziprasidone associated with weight loss in obese and overweight bipolar disorder patients

Abstract Objective To assess effectiveness and tolerability of open adjunctive ziprasidone for weight loss in obese/overweight patients with bipolar disorders (BD) in diverse mood states, taking weight gain-implicated psychotropic medications. Method 22 obese and three overweight BD patients (20 fem...

Full description

Saved in:
Bibliographic Details
Published in:Journal of psychiatric research 2011-08, Vol.45 (8), p.1128-1132
Main Authors: Wang, Po W, Hill, Shelley J, Childers, Meredith E, Chandler, Rebecca A, Rasgon, Natalie L, Ketter, Terence A
Format: Article
Language:English
Subjects:
Adult and adolescent clinical studies
Aged
Aged, 80 and over
Antipsychotic Agents - therapeutic use
Antipsychotic drugs
Biological and medical sciences
Bipolar disorder
Bipolar Disorder - complications
Bipolar Disorder - drug therapy
Bipolar disorders
Blood Glucose - drug effects
Body Mass Index
Depression
Dose-Response Relationship, Drug
Fasting
Female
Humans
Male
Medical sciences
Metabolic diseases
Middle Aged
Mood disorders
Moods
Neuropharmacology
Obesity
Obesity - complications
Obesity - drug therapy
Overweight - complications
Overweight - drug therapy
Pharmacology. Drug treatments
Piperazines - therapeutic use
Prospective Studies
Psychiatry
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Psychotropic drugs
Thiazoles - therapeutic use
Treatment
Waist Circumference
Weight loss
Weight Loss - drug effects
Ziprasidone
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective To assess effectiveness and tolerability of open adjunctive ziprasidone for weight loss in obese/overweight patients with bipolar disorders (BD) in diverse mood states, taking weight gain-implicated psychotropic medications. Method 22 obese and three overweight BD patients (20 female; 10 BD-I, 14 BD-II, 1 BD-NOS) with mean ± SD baseline body mass index (BMI) of 31.8 ± 2.5 kg/m2 received ZIP (mean final dose 190 ± 92 mg/day) for mean of 79.2 ± 23.2 days. Weight was assessed at six weekly and three biweekly visits. Subjects entered the study in diverse mood states. At baseline, 21 were taking second-generation antipsychotics, 7 lithium, and 1 valproate, which could be reduced/discontinued at investigators’ discretion. Results Weight and BMI decreased from baseline to endpoint by 4.5 ± 3.4 kg and 1.6 ± 1.2 kg/m2 , respectively, at weekly rates of 0.37 kg and 0.13 kg/m2 , respectively (all p  
ISSN:0022-3956
1879-1379
DOI:10.1016/j.jpsychires.2011.01.019